Every S-1 that Akari Therapeutics Plc (AKTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow AKTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AKTX filings page.
Akari Therapeutics is registering up to 2,500,000 American Depositary Shares (ADSs), representing 200,000,000,000 ordinary shares, for resale by White Lion Capital LLC. These ADSs back a $25 million equity purchase facility that Akari may tap at its discretion over a 36‑month period.
The registration includes 6,361 commitment ADSs that may be issued as consideration if Akari does not draw at least $625,000 from the facility within 180 days of effectiveness. Akari will not receive proceeds from White Lion’s resales, but will receive cash when it sells ordinary shares to White Lion under the Purchase Agreement. If all 2,500,000 ADSs are issued and sold, total ordinary shares outstanding would rise from 140,032,769,533 to 340,032,769,533, creating significant potential dilution and resale overhang for existing holders.
Akari Therapeutics is registering up to 1,139,818 American Depositary Shares (ADSs) with accompanying Series H and Series I warrants, plus related pre-funded and placement agent warrants, in a best-efforts primary offering. Each ADS represents 80,000 ordinary shares. The assumed combined public offering price is $6.58 per ADS with attached warrants, matching the May 7, 2026 Nasdaq closing price. If all ADSs are sold and no pre-funded warrants are issued or warrants exercised at closing, Akari estimates net proceeds of about $6.7 million, to fund research and development, working capital and general corporate purposes.
The structure allows certain investors to buy pre-funded warrants instead of ADSs to manage ownership caps of 4.99% or 9.99%. Common warrants are immediately exercisable, with Series H expiring in five years and Series I in 12 months. The offering has no minimum, so Akari could raise substantially less than the maximum, which its own risk disclosures say may limit its ability to execute its business plan. As of December 31 2025, the company had 90,536,879,533 ordinary shares outstanding and focuses on preclinical antibody-drug conjugate oncology programs, including lead candidate AKTX-101.
Akari Therapeutics, Plc is registering up to 34,680,906 American Depositary Shares (ADSs), representing 69,361,812,000 ordinary shares, for resale by existing investors. These ADSs are issuable from a mix of Series G warrants, pre-funded warrants, note exchange warrants and placement agent warrants tied to Akari’s December 2025 registered direct and private offerings and a December 2025 note exchange. Akari is not selling shares itself and will not receive proceeds from investor resales, though it may receive up to $8.9 million if warrants are exercised for cash. As of January 22, 2026, Akari had 45,781,350 ADSs (91,562,700,000 ordinary shares) outstanding plus 4,309,533 ordinary shares not in ADS form. The company is repositioned as an oncology business focused on antibody-drug conjugates, led by preclinical candidate AKTX-101, and reports a long history of operating losses, limited cash (about $2.5 million at September 30, 2025), material weaknesses in internal controls, and significant ongoing capital needs, all highlighted in extensive risk factors.
Akari Therapeutics, PLC is registering up to 12,750,000,000 ordinary shares, represented by 6,375,000 ADSs, for resale by selling shareholders who hold warrants issued in an October 2025 financing. Akari is not selling any ADSs in this transaction and will not receive proceeds from these resales, though it may receive up to $6.25 million if the warrants are exercised for cash.
The registered shares come from Series E and Series F warrants sold in an October 2025 private placement and placement agent warrants. As of November 13, 2025, Akari had 71,479,461,523 ordinary shares outstanding, and its ADSs traded at $0.529 on November 14, 2025. Following its 2024 merger with Peak Bio, Akari is focused on oncology, developing next‑generation antibody-drug conjugates, with lead candidate AKTX-101 in preclinical development.